Advertisement
Canada markets close in 3 hours 34 minutes

  • S&P/TSX

    22,343.96
    -31.87 (-0.14%)
     

  • S&P 500

    5,217.46
    +3.38 (+0.06%)
     

  • DOW

    39,483.48
    +95.72 (+0.24%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.61
    -0.65 (-0.82%)
     

  • Bitcoin CAD

    83,519.95
    -1,981.34 (-2.32%)
     

  • CMC Crypto 200

    1,261.24
    -96.77 (-7.13%)
     

  • GOLD FUTURES

    2,371.50
    +31.20 (+1.33%)
     

  • RUSSELL 2000

    2,057.65
    -15.98 (-0.77%)
     

  • 10-Yr Bond

    4.5020
    +0.0530 (+1.19%)
     

  • NASDAQ

    16,323.06
    -23.20 (-0.14%)
     

  • VOLATILITY

    12.80
    +0.11 (+0.87%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS DOW EYES GAIN FOR 8TH STRAIGHT SESSION

U.S. consumer sentiment tumbles in May as inflation, interest rate worries take hold

Turning Point Therapeutics: 4Q Earnings Snapshot

Associated Press
Updated ·1 min read

SAN DIEGO (AP) _ Turning Point Therapeutics Inc. (TPTX) on Monday reported a loss of $47.4 million in its fourth quarter.

The San Diego-based company said it had a loss of $1.02 per share.

The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 94 cents per share.

For the year, the company reported that its loss widened to $157.3 million, or $3.85 per share. Revenue was reported as $25 million.

Turning Point Therapeutics shares have fallen 0.5% since the beginning of the year. In the final minutes of trading on Monday, shares hit $121.22, more than doubling in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TPTX at https://www.zacks.com/ap/TPTX